Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia
- PMID: 28674504
- PMCID: PMC5474459
- DOI: 10.3389/fpsyt.2017.00104
Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia
Abstract
Inflammation may play a role in schizophrenia; however, subgroups with immune regulation dysfunction may serve as distinct illness phenotypes with potential different treatment and prevention strategies. Emerging data show that about 30% of people with schizophrenia have elevated antigliadin antibodies of the IgG type, representing a possible subgroup of schizophrenia patients with immune involvement. Also, recent data have shown a high correlation of IgG-mediated antibodies between the periphery and cerebral spinal fluid in schizophrenia but not healthy controls, particularly AGA IgG suggesting that these antibodies may be crossing the blood-brain barrier with resulting neuroinflammation. Proton magnetic resonance spectroscopy (MRS) is a non-invasive technique that allows the quantification of certain neurochemicals in vivo that may proxy inflammation in the brain such as myoinositol and choline-containing compounds (glycerophosphorylcholine and phosphorylcholine). The objective of this exploratory study was to examine the relationship between serum AGA IgG levels and MRS neurochemical levels. We hypothesized that higher AGA IgG levels would be associated with higher levels of myoinositol and choline-containing compounds (glycerophosphorylcholine plus phosphorylcholine; GPC + PC) in the anterior cingulate cortex. Thirty-three participants with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder had blood drawn and underwent neuroimaging using MRS within 9 months. We found that 10/33 (30%) had positive AGA IgG (≥20 U) similar to previous findings. While there were no significant differences in myoinositol and GPC + PC levels between patients with and without AGA IgG positivity, there were significant relationships between both myoinositol (r = 0.475, p = 0.007) and GPC + PC (r = 0.36, p = 0.045) with AGA IgG levels. This study shows a possible connection of AGA IgG antibodies to putative brain inflammation as measured by MRS in schizophrenia.
Keywords: GPC + PC; antibody; gliadin; gluten; inflammation; myoinositol; neuroimaging; schizophrenia.
Figures



Similar articles
-
Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG).Schizophr Res. 2019 Jun;208:414-419. doi: 10.1016/j.schres.2019.01.007. Epub 2019 Jan 24. Schizophr Res. 2019. PMID: 30685393 Free PMC article.
-
Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study.J Psychiatry Neurosci. 2019 Jul 1;44(4):269-276. doi: 10.1503/jpn.180174. J Psychiatry Neurosci. 2019. PMID: 30938127 Free PMC article. Clinical Trial.
-
Anti gliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia.Brain Behav Immun. 2018 Mar;69:57-59. doi: 10.1016/j.bbi.2017.10.020. Epub 2017 Oct 23. Brain Behav Immun. 2018. PMID: 29074356 Free PMC article.
-
Serum antigliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis.J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1174-1180. doi: 10.1136/jnnp-2018-318215. Epub 2018 Jun 4. J Neurol Neurosurg Psychiatry. 2018. PMID: 29866704 Free PMC article.
-
Anti-gliadin antibodies in non-celiac gluten sensitivity.Minerva Gastroenterol Dietol. 2017 Mar;63(1):1-4. doi: 10.23736/S1121-421X.16.02351-5. Epub 2016 Nov 15. Minerva Gastroenterol Dietol. 2017. PMID: 27845509 Review.
Cited by
-
Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG).Schizophr Res. 2019 Jun;208:414-419. doi: 10.1016/j.schres.2019.01.007. Epub 2019 Jan 24. Schizophr Res. 2019. PMID: 30685393 Free PMC article.
-
Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study.J Psychiatry Neurosci. 2019 Jul 1;44(4):269-276. doi: 10.1503/jpn.180174. J Psychiatry Neurosci. 2019. PMID: 30938127 Free PMC article. Clinical Trial.
-
Upregulation of the Intestinal Paracellular Pathway with Breakdown of Tight and Adherens Junctions in Deficit Schizophrenia.Mol Neurobiol. 2019 Oct;56(10):7056-7073. doi: 10.1007/s12035-019-1578-2. Epub 2019 Apr 10. Mol Neurobiol. 2019. PMID: 30972627
-
Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia.Schizophr Res. 2024 Jul;269:71-78. doi: 10.1016/j.schres.2024.05.001. Epub 2024 May 14. Schizophr Res. 2024. PMID: 38749320 Free PMC article. Clinical Trial.
-
Autoimmune phenotypes in schizophrenia reveal novel treatment targets.Pharmacol Ther. 2018 Sep;189:184-198. doi: 10.1016/j.pharmthera.2018.05.005. Epub 2018 May 6. Pharmacol Ther. 2018. PMID: 29742478 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous